Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 31, 1997

View Archived Issues

New immunosuppressants in the pipeline at Merck & Co.

IL-5 receptor ligands reported by Glaxo Wellcome

New antifungals disclosed by Schering-Plough

New photodynamic agents reported by Novartis

Improved method for vWF purification developed by Bayer

HMR discloses new anti-HIV agents

UPSA claims new COX-2 inhibitors for inflammation, pain and other disorders

New orally active antihypertensive compounds prepared at Rotta

Cytogen updates stockholders

Potent and selective AMPA antagonist from Roche

FR-208419: a new dual CCK-A and CCK-B/gastrin receptor antagonist

Banyu searches for potent, orally bioavailable FXa inhibitors

Favorable phase III trial results reported for HER2 monoclonal antibody

Cambridge Antibody Technology: FY 1997 highlights

FDA deems Provigil approvable

Raxar --new once-daily fluoroquinolone-- now available in U.S.

Commencement of phase II trials of LiquiVent for adult ARDS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...